The Moderna and Pfizer vaccines are on line and delivering vaccinations. What about the J&J (Janssen) vaccine and their single-shot viral vector vaccine? While it has lower efficacy than the mRNA-based products, it could be a stand-in on an emergency basis in Europe for those who won’t receive an mRNA-based vaccine for months. Perhaps this could introduce intermediate level protection?
What about the Novavax preliminary results revealing an 89.3% efficacy? Could this not be accelerated? Other ideas sent into the TrialSite from very insightful readers suggest studying the UK approach, where they allow the time gap between doses to extend to 12 weeks. This offers protection to double the population in an accelerated manner. Of course, the counter goes that there just isn’t sufficient data to support such action from trials, but what is the probability that immunity would wane in that time frame since it’s not observed in natural immunity? Not an ideal situation, but the impending risk of more escape of far more dangerous, more transmissible mutant variants raises the alarm for action. (Trialsitenews.com)